A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN™ for Improving Sleep
Open Access
- 24 July 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (8) , 977
Abstract
The phytocannabinoid cannabinol (CBN) has a potential mechanism of action as an alternative sleep aid but there is minimal evidence to support its effectiveness. The aim of this randomized, double-blind, placebo-controlled study was to assess the safety and effects of three formulations of a hemp-derived CBN sleep aid, TruCBN™ [25 mg (n = 206), 50 mg (n = 205), 100 mg (n = 203)], on sleep quality (PROMIS Sleep Disturbance 8A), relative to placebo (n = 204). The effectiveness and safety of these formulations relative to 4 mg of melatonin (n = 202) was assessed. Exploratory measures were stress (PROMIS Stress 4A), anxiety (Anxiety 4A), pain (PROMIS™ PEG), and well-being (WHO 5). All groups and the 4 mg melatonin group experienced significant improvement in sleep quality relative to the placebo group with no significant differences between any group and the melatonin group. Participants taking 100 mg showed a larger decrease in stress compared to the placebo group. There were no significant differences in anxiety, pain, well-being, or the frequency of side effects between any group and the placebo group. There was no significant difference in improvements in sleep quality between any of the treatment groups and the 4 mg melatonin group. Orally ingested CBN, at 25 mg, 50 mg, and 100 mg, is a safe and effective alternative for the improvement of sleep.Keywords
All Related Versions
Funding Information
- Floraworks
This publication has 24 references indexed in Scilit:
- The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled TrialJournal of the American Nutrition Association, 2023
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trialsSleep Medicine Reviews, 2021
- Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trialsJournal of Neurology, 2021
- Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studiesSleep Medicine Reviews, 2020
- Exogenous melatonin as a treatment for secondary sleep disorders: A systematic review and meta-analysisFrontiers in Neuroendocrinology, 2019
- Cannabis, Cannabinoids, and Sleep: a Review of the LiteratureCurrent Psychiatry Reports, 2017
- Real-World Evidence — What Is It and What Can It Tell Us?New England Journal of Medicine, 2016
- InsomniaJAMA, 2013
- Sleep deprivation attenuates inflammatory responses and ischemic cell deathExperimental Neurology, 2009
- Neurocognitive Consequences of Sleep DeprivationSeminars in Neurology, 2005